lps elisa Search Results


90
Krishgen Biosystems kribiolisa human elisa kit
CCL2 levels in GCF and Isolation of CD14+ monocytes. (A) <t>ELISA</t> assay was performed to assess the protein levels of CCL2 in GCF from normal subjects and periodontitis patients. (B–H) Flow Cytometry based characterization of CD14+ cells from GCF and comparative analysis of CD14+ cells in GCF from normal subjects and periodontitis patients. ns not significant, *p < 0.05, **p < 0.001. CCL2: C–C motif chemokine ligand 2.
Kribiolisa Human Elisa Kit, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc08116999-35-7-11?v=Krishgen+Biosystems
Average 90 stars, based on 1 article reviews
kribiolisa human elisa kit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

94
Shanghai Korain Biotech Co Ltd human elisa kits
CCL2 levels in GCF and Isolation of CD14+ monocytes. (A) <t>ELISA</t> assay was performed to assess the protein levels of CCL2 in GCF from normal subjects and periodontitis patients. (B–H) Flow Cytometry based characterization of CD14+ cells from GCF and comparative analysis of CD14+ cells in GCF from normal subjects and periodontitis patients. ns not significant, *p < 0.05, **p < 0.001. CCL2: C–C motif chemokine ligand 2.
Human Elisa Kits, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pm41683447-250-15-19?v=Shanghai+Korain+Biotech+Co+Ltd
Average 94 stars, based on 1 article reviews
human elisa kits - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
Cusabio rat lps elisa kit
CCL2 levels in GCF and Isolation of CD14+ monocytes. (A) <t>ELISA</t> assay was performed to assess the protein levels of CCL2 in GCF from normal subjects and periodontitis patients. (B–H) Flow Cytometry based characterization of CD14+ cells from GCF and comparative analysis of CD14+ cells in GCF from normal subjects and periodontitis patients. ns not significant, *p < 0.05, **p < 0.001. CCL2: C–C motif chemokine ligand 2.
Rat Lps Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc09519788-60-8-12?v=Cusabio
Average 93 stars, based on 1 article reviews
rat lps elisa kit - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

96
Cusabio mouse lps elisa kit
CCL2 levels in GCF and Isolation of CD14+ monocytes. (A) <t>ELISA</t> assay was performed to assess the protein levels of CCL2 in GCF from normal subjects and periodontitis patients. (B–H) Flow Cytometry based characterization of CD14+ cells from GCF and comparative analysis of CD14+ cells in GCF from normal subjects and periodontitis patients. ns not significant, *p < 0.05, **p < 0.001. CCL2: C–C motif chemokine ligand 2.
Mouse Lps Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pm37343363-89-13-17?v=Cusabio
Average 96 stars, based on 1 article reviews
mouse lps elisa kit - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

93
Cusabio lps elisa
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Lps Elisa, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc07379883-84-14-16?v=Cusabio
Average 93 stars, based on 1 article reviews
lps elisa - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Cusabio lipopolysaccharide
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Lipopolysaccharide, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/10__1096_slash_fj__202001364r-107-17-22?v=Cusabio
Average 93 stars, based on 1 article reviews
lipopolysaccharide - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

93
Cusabio elisa kits
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Elisa Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc09426487-265-32-34?v=Cusabio
Average 93 stars, based on 1 article reviews
elisa kits - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
MyBiosource Biotechnology elisa commercial kit for lps
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Elisa Commercial Kit For Lps, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc08834517-144-16-19?v=MyBiosource+Biotechnology
Average 90 stars, based on 1 article reviews
elisa commercial kit for lps - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Cloud-Clone corp elisa kit
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Elisa Kit, supplied by Cloud-Clone corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc10451159-196-6-9?v=Cloud-Clone+corp
Average 90 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
USCN Life endotoxin elisa kit
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Endotoxin Elisa Kit, supplied by USCN Life, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pm22931549-53-0-6?v=USCN+Life
Average 90 stars, based on 1 article reviews
endotoxin elisa kit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
US Biological Life Sciences lipopolysaccharides (lps) bioassay elisa kit
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Lipopolysaccharides (Lps) Bioassay Elisa Kit, supplied by US Biological Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pmc04508840-51-8-13?v=US+Biological+Life+Sciences
Average 90 stars, based on 1 article reviews
lipopolysaccharides (lps) bioassay elisa kit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
BlueGene Biotech mouse lipopolysaccharide (lps) elisa kit
Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) <t>LPS</t> levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by <t>ELISA.</t> (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.
Mouse Lipopolysaccharide (Lps) Elisa Kit, supplied by BlueGene Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lps+elisa/pm30696986-80-16-24?v=BlueGene+Biotech
Average 90 stars, based on 1 article reviews
mouse lipopolysaccharide (lps) elisa kit - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


CCL2 levels in GCF and Isolation of CD14+ monocytes. (A) ELISA assay was performed to assess the protein levels of CCL2 in GCF from normal subjects and periodontitis patients. (B–H) Flow Cytometry based characterization of CD14+ cells from GCF and comparative analysis of CD14+ cells in GCF from normal subjects and periodontitis patients. ns not significant, *p < 0.05, **p < 0.001. CCL2: C–C motif chemokine ligand 2.

Journal: Saudi Journal of Biological Sciences

Article Title: Gingival crevicular fluid infiltrating CD14+ monocytes promote inflammation in periodontitis

doi: 10.1016/j.sjbs.2021.02.049

Figure Lengend Snippet: CCL2 levels in GCF and Isolation of CD14+ monocytes. (A) ELISA assay was performed to assess the protein levels of CCL2 in GCF from normal subjects and periodontitis patients. (B–H) Flow Cytometry based characterization of CD14+ cells from GCF and comparative analysis of CD14+ cells in GCF from normal subjects and periodontitis patients. ns not significant, *p < 0.05, **p < 0.001. CCL2: C–C motif chemokine ligand 2.

Article Snippet: CCL2 protein levels were analyzed using the KRIBIOLISA human ELISA kit (Krishgen Biosystems, Los Angeles, CA, USA).

Techniques: Isolation, Enzyme-linked Immunosorbent Assay, Flow Cytometry

Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) LPS levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by ELISA. (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.

Journal: Frontiers in Pharmacology

Article Title: Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis

doi: 10.3389/fphar.2020.01098

Figure Lengend Snippet: Elevated levels of BPI present in plasma and BAL of people with CF. (A , B) LPS levels in CF plasma and BAL correlated with CF-ABLE score. Quantification of an association between variables was achieved by Spearman correlation. (C , D) Comparative analysis of BPI present in plasma or BAL of Phe508del homozygous PWCF (CF), healthy controls (HC) or NCFB patients was performed by ELISA. (C) BPI levels were significantly increased in plasma of CF compared to HC (n=22 and n=14 subjects per group, respectively, p=0.007, Mann Whitney U-test). (D) BAL levels of BPI were significantly increased in CF (n=5) compared to HC (n=4) or NCFB patients (n=5) (p<0.0001, One-way ANOVA, followed by Bonferroni post-hoc test for selected groups). (E) BAL samples from HC, CF, NCFB or COPD were subjected to SDS-PAGE and Western blot analysis for BPI. An immuno-band of increased intensity for BPI was detected in CF BAL samples (top panels). Lower panel, a control immunoblot to ensure BPI specificity. The blot was halved, with one half probed with secondary antibody only with no BPI immune-bands visible (↑ indicates where blot was cut). Human BPI (hBPI) was used as a positive control. All measurements are means ± SEM from biological replicates.

Article Snippet: Lipopolysaccharide (LPS) was quantified in plasma and BAL of PWCF ( ) using an LPS ELISA (Cusabio: catalog number CSB-E09945h).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, SDS Page, Western Blot, Control, Positive Control

Increased levels of plasma autoantibodies and IgG-bound BPI in CF airway samples. (A) IgG autoantibodies against BPI were quantified in plasma of PWCF (CF, n=30) or healthy controls (HC, n=37). A significant increase in the titre of BPI autoantibodies were detected in CF (p<0.0001, Mann-Whitney U test). Positivity was set as 10 U/ml as indicated by the hatched line. All CF samples were positive for BPI autoantibodies. Increased circulating IgG BPI antibody level in CF individuals determined by ELISA. (B) Plasma samples from HC (n=38), CF (n=28) and CF individuals receiving ivacaftor treatment (n=10). No difference in levels of circulating anti-BPI IgG autoantibodies between CF and CF individuals receiving ivacaftor treatment (p=0.39). (C) Representative Coomassie blue stained SDS gel of purified IgG from CF BAL. Protein G Sepharose was used to isolate IgG from BAL of Phe508del homozygous PWCF. Starting BAL sample (St), unbound material (Un) or purified bound IgG (Bd) with or without DTT reduction are presented. Purified IgG (150 kDa, closed arrow), and the heavy (50 kDa) and light chains (25 kDa) of IgG are indicated (open arrows) (1 representative images of n = 5 biological repeats). (D) Protein G Sepharose was used to isolate IgG-BPI complexes from CF BAL. Reactions were analyzed by immunoblotting for BPI positivity using a mouse monoclonal anti-BPI antibody. Starting BAL sample (St), unbound material (Un) or IgG-bound BPI (Bd) are presented. Human BPI (hBPI) was used as a positive control (55 kDa). A control immunoblot to ensure BPI specificity omitted primary antibody (right hand panel), with no immune-band apparent. 3 representative images of n=5 biological repeats.

Journal: Frontiers in Pharmacology

Article Title: Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis

doi: 10.3389/fphar.2020.01098

Figure Lengend Snippet: Increased levels of plasma autoantibodies and IgG-bound BPI in CF airway samples. (A) IgG autoantibodies against BPI were quantified in plasma of PWCF (CF, n=30) or healthy controls (HC, n=37). A significant increase in the titre of BPI autoantibodies were detected in CF (p<0.0001, Mann-Whitney U test). Positivity was set as 10 U/ml as indicated by the hatched line. All CF samples were positive for BPI autoantibodies. Increased circulating IgG BPI antibody level in CF individuals determined by ELISA. (B) Plasma samples from HC (n=38), CF (n=28) and CF individuals receiving ivacaftor treatment (n=10). No difference in levels of circulating anti-BPI IgG autoantibodies between CF and CF individuals receiving ivacaftor treatment (p=0.39). (C) Representative Coomassie blue stained SDS gel of purified IgG from CF BAL. Protein G Sepharose was used to isolate IgG from BAL of Phe508del homozygous PWCF. Starting BAL sample (St), unbound material (Un) or purified bound IgG (Bd) with or without DTT reduction are presented. Purified IgG (150 kDa, closed arrow), and the heavy (50 kDa) and light chains (25 kDa) of IgG are indicated (open arrows) (1 representative images of n = 5 biological repeats). (D) Protein G Sepharose was used to isolate IgG-BPI complexes from CF BAL. Reactions were analyzed by immunoblotting for BPI positivity using a mouse monoclonal anti-BPI antibody. Starting BAL sample (St), unbound material (Un) or IgG-bound BPI (Bd) are presented. Human BPI (hBPI) was used as a positive control (55 kDa). A control immunoblot to ensure BPI specificity omitted primary antibody (right hand panel), with no immune-band apparent. 3 representative images of n=5 biological repeats.

Article Snippet: Lipopolysaccharide (LPS) was quantified in plasma and BAL of PWCF ( ) using an LPS ELISA (Cusabio: catalog number CSB-E09945h).

Techniques: Clinical Proteomics, MANN-WHITNEY, Enzyme-linked Immunosorbent Assay, Staining, SDS-Gel, Purification, Western Blot, Positive Control, Control